Antiviral drugs for treatment of patients infected with pandemic (H1N1) 2009 virus

Emerging Infectious Diseases

Volumn 15, Issue 10, 2009, Pages

  Hartley, David M ^a   Nelson, Noele P ^a   Perencevich, Eli N ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; DRUG EFFICACY; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H1N1; LETTER; MONOTHERAPY; MORTALITY; NONHUMAN; PANDEMIC; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 70349970947     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1511.090720     Document Type: Letter

References (10)

1. World Health Organization. Global alert and response: pandemic (H1N1) 2009 - update 60 [cited 2009 Aug 11]. Available from http://www.who.int/csr/don/ 2009-08-04/en/index.html
2. National Pandemic Flu Service. Welcome to the National Pandemic Flu Service [cited 2009 Aug 17]. Available from https://www.pandemicflu.direct.gov. uk
3. Kitching A, Roche A, Balasegaram S, Heathcock R, Maguire H. Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009: an internetbased cross-sectional survey. Euro Surveill. 2009;14:19287. PubMed
4. Centers for Disease Control and Prevention. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis - North Carolina, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:969-972 PubMed
5. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007: lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill. 2009;14:19112.
6. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12:603-616 PubMed (Pubitemid 47235503)
7. Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis. 2009;48:1254-1256 PubMed DOI: 10.1086/598989
8. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, Schweiger B, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis. 2009;15:552-560 PubMed DOI: 10.3201/eid1504.081280
9. Lipsitch M, Cohen T, Murray M, Levin BR. Antiviral resistance and the control of pandemic influenza. PLoS Med. 2007;4:e15. PubMed DOI: 10.1371/journal.pmed.0040015 (Pubitemid 46191826)
10. Uyeki TM, Prasad R, Vukotich C, Stebbins S, Rinaldo CR, Ferng YH, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis. 2009;48:e89-92. PubMed DOI: 10.1086/597828